ADGRF5 and posterior cortical atrophy: It is possible to design targeted therapies against specific cells in the TME (such as STEAP4+ ADGRF5+ fibroblasts) to block or slow down the metastatic process of PCa and to improve the therapeutic efficacy and survival of patients.